Irreversible Electroporation for Treatment of Solid Abdominal Tumors

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03169439
Collaborator
(none)
25
1
25

Study Details

Study Description

Brief Summary

Irreversible electroporation (IRE) is a novel non-thermal ablation modality with promise for revolutionizing the treatment for local solid tumors.

With the growing demand for alternative and less invasive treatments for localized tumors, the investigators have seen the development and investigation of several tissue ablation modalities, including radiofrequency ablation (RFA), microwave ablation, and cryoablation. Although these modalities have been efficacious, they have some disadvantages owing to their reliance on thermal energy for creating cell death.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Irreversible electroporation
N/A

Detailed Description

Irreversible electroporation is novel in that it does not use thermal energy, but electrical energy to produce focused cell death while sparing the normal extracellular matrix, nearby vessels, and structures, while allowing for rapid normal tissue regrowth.

Unlike thermal ablation modalities, Irreversible electroporation does not require significant consideration for dissipation of thermal energy, or heat sink, and has less complications relating to damage of normal soft tissue, eliminating a major cause of treatment failure.

Irreversible electroporation is a novel minimally invasive tumor/tissue ablation technique that can be used under guidance of ultrasound (US) or computed tomography (CT), without inducing thermal damaging effects, and with preservation of the surrounding vital structures such as vessels, bile ducts, urethra, and nerves which remain intact to function normally, even in locally advanced tumors. The technique depends upon inducing apoptotic non-necrotic cell death in short procedure time.

It has the advantage of allowing quick tissue regeneration. Irreversible electroporation treatment time is significantly shorter than traditional thermal ablation modalities, usually in few minutes range, and allows for treating considerably larger lesions than thermal ablation modalities.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Irreversible Electroporation for Treatment of Solid Abdominal Tumors
Anticipated Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Apr 1, 2019
Anticipated Study Completion Date :
Aug 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Other: hepatic focal lesions and pancreatic masses

Procedure: Irreversible electroporation
minimal invasive ablative technique for tumors

Outcome Measures

Primary Outcome Measures

  1. The ablation success [3 months]

    the ability to deliver planned therapy and to have no residual

Secondary Outcome Measures

  1. Local recurrence [3,6 and 12 months]

    defined as re appearance of viable tumor after period during which no tumor could be detected

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with unresectable solid abdominal tumors (hepatic, pancreatic, porta hepatis,…).

  • The mass measures less than 4 cm.

  • Associated with no or oligo metastatic lesions

Exclusion Criteria:
  • Patients with cardiac arrhythmia and pacemaker.

  • Patients unfit for general anesthesia.

  • The lesion size is larger than 4 cm.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jolie Welson, principle investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT03169439
Other Study ID Numbers:
  • IREAT
First Posted:
May 30, 2017
Last Update Posted:
May 30, 2017
Last Verified:
May 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2017